GlassScriptPhysician profile
Melissa Bibb
NPI 1063865608
$1,704.00
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.73 · 2022: $530 · 2023: $1,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $423.46 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $193.80 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $177.52 | 2022-2023 | Farxiga |
| Sumitomo Pharma America, INC. | $162.63 | 2023 | Gemtesa, Aptiom |
| Astellas Pharma US INC | $110.83 | 2023 | Veozah, Myrbetriq |
| Alkermes, INC. | $91.51 | 2022-2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $82.60 | 2022-2023 | Rexulti, Abilify Maintena |
| Pfizer INC. | $74.00 | 2023 | |
| Glaxosmithkline, LLC. | $67.77 | 2021-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Almatica Pharma LLC | $58.13 | 2023 | Gralise |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.58 | 2023 | Xifaxan |
| Ucb, INC. | $32.19 | 2023 | Nayzilam |
| Inogen, INC. | $31.87 | 2023 | Inogen One G3 Oxygen Concentrator |
| Ardelyx, INC. | $23.00 | 2023 | Ibsrela |
| Exact Sciences Corporation | $21.77 | 2023 | Cologuard Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $21.77 | 2023 | Mounjaro |
| Axonics, INC. | $21.20 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.03 | 2022 | |
| Si-Bone, INC. | $20.96 | 2023 | |
| Novo Nordisk INC | $14.38 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Bibb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.